Belgium· BE-AMP-SAM522275-00
Prevymis 240 mg
A letermovir product containing letermovir, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Letermovir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX18 (letermovir), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 10 of them publish a price we can compare per daily dose
Letermovir · ATC J05AX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of letermovir costs, country by country.
Normalised to the WHO defined daily dose (0.48 g), the median price runs from $9.77 in France to $563.69 in Italy — a ×58 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Letermovir · price per daily dose (0.48 g)
USD · FX 28 Sept 2026
- IT Italy$563.69
- CH Switzerland$371.41
- FR France$9.77
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Letermovir
- Manufacturer
- Merck Sharp & Dohme
- Country
- Belgium (BE)
- ATC code
- J05AX18
- ATC class
- Letermovir
- Defined daily dose
- 0.48 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7726425
- be_apb3718871
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
222 interactions on record for letermovir.
Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Letermovir · interactions on record
222 records
- 38 severe
- 172 moderate
- 12 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- CilostazolB01AC23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Letermovir in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayPrevymisMerck Sharp & Dohme B.V. (1)
- CzechiaPREVYMISMerck Sharp & Dohme B.V., Haarlem
- FinlandPREVYMISMerck Sharp & Dohme B.V.
- IrelandPREVYMIS 240 mg Concentrate for solution for infusionMerck Sharp & Dohme BV
- IcelandPrevymisMerck Sharp & Dohme B.V.*
- SwedenPREVYMIS 240 mg Koncentrat till infusionsvätska, lösningMerck Sharp & Dohme BV
- SwitzerlandPrevymis 120 mg, GranulatMSD Merck Sharp & Dohme AG
- United StatesPREVYMISMerck Sharp & Dohme LLC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Prevymis
- Liechtenstein · Prevymis
- Norway · Prevymis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e6e8a53b-aace-4cf6-b28f-aa32ca2f4f39 GET /v1/drugs/e6e8a53b-aace-4cf6-b28f-aa32ca2f4f39?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Prevymis 240 mg",
"name_fr": "Prevymis 240 mg",
"name_nl": "Prevymis 240 mg",
"amp_code": "SAM522275-00",
"strengths": [
"20.0000",
"1800.0000",
"23.0000"
],
"pack_count": 1,
"substances": [
"Letermovir",
"Hydroxypropylbetadex",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Letermovir",
"authorisation_numbers": [
"EU/1/17/1245/003"
]
}See everything about letermovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.